Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes.
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
10 03 2021
10 03 2021
Historique:
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
13
1
2021
Statut:
ppublish
Résumé
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible of coronavirus disease 2019 (COVID-19), has devastated public health services and economies worldwide. Despite global efforts to contain the COVID-19 pandemic, SARS-CoV-2 is now found in over 200 countries and has caused an upward death toll of over 1 million human lives as of November 2020. To date, only one Food and Drug Administration (FDA)-approved therapeutic drug (Remdesivir) and a monoclonal antibody, MAb (Bamlanivimab) are available for the treatment of SARS-CoV-2. As with other viruses, studying SARS-CoV-2 requires the use of secondary approaches to detect the presence of the virus in infected cells. To overcome this limitation, we have generated replication-competent recombinant (r)SARS-CoV-2 expressing fluorescent (Venus or mCherry) or bioluminescent (Nluc) reporter genes. Vero E6 cells infected with reporter-expressing rSARS-CoV-2 can be easily detected via fluorescence or luciferase expression and display a good correlation between reporter gene expression and viral replication. Moreover, rSARS-CoV-2 expressing reporter genes have comparable plaque sizes and growth kinetics to those of wild-type virus, rSARS-CoV-2/WT. We used these reporter-expressing rSARS-CoV-2 to demonstrate their feasibility to identify neutralizing antibodies (NAbs) or antiviral drugs. Our results demonstrate that reporter-expressing rSARS-CoV-2 represent an excellent option to identify therapeutics for the treatment of SARS-CoV-2, where reporter gene expression can be used as valid surrogates to track viral infection. Moreover, the ability to manipulate the viral genome opens the feasibility of generating viruses expressing foreign genes for their use as vaccines for the treatment of SARS-CoV-2 infection.
Identifiants
pubmed: 33431557
pii: JVI.02209-20
doi: 10.1128/JVI.02209-20
pmc: PMC8092710
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 American Society for Microbiology.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Sci Total Environ. 2020 Jul 10;725:138277
pubmed: 32278175
PLoS One. 2014 May 19;9(5):e97695
pubmed: 24842154
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Sci Rep. 2015 Jun 12;5:11346
pubmed: 26068081
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
J Vis Exp. 2019 Jun 24;(148):
pubmed: 31282877
Retrovirology. 2020 May 19;17(1):12
pubmed: 32430080
Cont Lens Anterior Eye. 2020 Jun;43(3):196-203
pubmed: 32273245
ACS Chem Biol. 2012 Nov 16;7(11):1848-57
pubmed: 22894855
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Virol. 2005 Dec;79(24):15511-24
pubmed: 16306622
J Virol Methods. 2021 Jan;287:113995
pubmed: 33068703
Infect Dis Poverty. 2020 Apr 7;9(1):34
pubmed: 32264957
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1206-11
pubmed: 10655509
Curr Protoc Microbiol. 2020 Dec;59(1):e126
pubmed: 33048448
Chemotherapy. 2019;64(5-6):215-223
pubmed: 32259829
J Virol. 2013 Aug;87(15):8272-81
pubmed: 23698304
mBio. 2017 May 30;8(3):
pubmed: 28559489
Cold Spring Harb Protoc. 2012 Aug 01;2012(8):
pubmed: 22854570
Nat Commun. 2015 Mar 25;6:6600
pubmed: 25807527
Anesth Analg. 2020 Jul;131(1):93-96
pubmed: 32243297
Cell Rep Med. 2021 Mar 16;2(3):100218
pubmed: 33649747
Curr Protoc Microbiol. 2013;Chapter 15:Unit 15G.4
pubmed: 23686828
Bioinformatics. 2018 Mar 1;34(5):867-868
pubmed: 29096012
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1653-1656
pubmed: 33382675
Sci Rep. 2015 Jun 02;5:10332
pubmed: 26035795
mBio. 2020 Sep 25;11(5):
pubmed: 32978313
J Virol. 2010 Feb;84(4):2157-63
pubmed: 19939917
Virus Res. 2008 Apr;133(1):113-21
pubmed: 18045721
Viruses. 2015 Oct 13;7(10):5319-27
pubmed: 26473913
Antiviral Res. 2019 Aug;168:82-90
pubmed: 31150677
Nat Methods. 2007 Sep;4(9):741-6
pubmed: 17721542
PLoS One. 2016 Jan 25;11(1):e0147723
pubmed: 26809059
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Nat Commun. 2015 Mar 06;6:6378
pubmed: 25744559
Virus Res. 2016 Feb 2;213:69-81
pubmed: 26590325
J Virol. 2019 May 1;93(10):
pubmed: 30867298
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26946-26954
pubmed: 33028676
Virology. 2015 Feb;476:206-216
pubmed: 25553516
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Nucleic Acids Res. 2012 Dec;40(22):11189-201
pubmed: 23066108
Nature. 2020 Apr 7;:
pubmed: 32265538
J Virol. 2012 Feb;86(3):1433-48
pubmed: 22114331
Antiviral Res. 2011 Jul;91(1):11-9
pubmed: 21575658
Antiviral Res. 2013 Feb;97(2):198-205
pubmed: 23267829
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11531-6
pubmed: 20534532
Viruses. 2016 Jun 23;8(7):
pubmed: 27347991
Mol Imaging. 2007 Jul-Aug;6(4):269-76
pubmed: 17711782